Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2021 Feb;10(2):636-650.
doi: 10.21037/tlcr-20-1099.

Comprehensive genomic profiling of combined small cell lung cancer

Jing Zhang  1 , Liping Zhang  2 , Jie Luo  3 , Tao Ge  1 , Pengyu Fan  1 , Liangdong Sun  1 , Likun Hou  2 , Junqiang Li  4 , Huansha Yu  1 , Chunxiao Wu  5 , Yuming Zhu  1 , Chunyan Wu  2 , Gening Jiang  1 , Giancarlo Troncone  6 , Jyoti Malhotra  7 , Katsuhiro Okuda  8 , Mariacarmela Santarpia  9 , Rita Zamarchi  10 , Taichiro Goto  11 , Andrés F Cardona  12   13   14 , Jianfang Xu  3 , Qiankun Chen  1 , Zhonghong Zhang  15 , Peng Zhang  1 ; written on behalf of the AME Lung Cancer Collaborative Group
Affiliations

Comprehensive genomic profiling of combined small cell lung cancer

Jing Zhang et al. Transl Lung Cancer Res. 2021 Feb.

Abstract

Background: Combined small cell lung cancer (CSCLC) is an uncommon and heterogeneous subtype of small cell lung cancer (SCLC). However, there is limited data concerning the different molecular changes and clinical features in CSCLC compared to pure SCLC.

Methods: The clinical and pathological characteristics of pure SCLC and CSCLC patients were analyzed. Immunohistochemistry and microdissection were performed to isolate the CSCLC components. Further molecular analysis was carried out by next-generation sequencing (NGS) in 12 CSCLC and 30 pure SCLC.

Results: There were no significant differences in clinical features between CSCLC and pure SCLC. Overall survival (OS) of CSCLC patients was worse than pure SCLC (P=0.005). NGS results indicated that TP53 and RB1 were the most frequently mutated genes in both CSCLC (83.33% and 66.67%) and pure SCLC (80.00% and 63.33%) groups. However, less than 10% common mutations were found in both CSCLC and pure SCLC. When analyzing the data of SCLC and non-small cell lung cancer (NSCLC) components of CSCLC, more than 50% common mutations, and identical genes with mutations were detected. Moreover, there were also common biological processes and signaling pathways identified in CSCLC and pure SCLC, in addition to SCLC and NSCLC components.

Conclusions: There were no significant differences in terms of clinical features between CSCLC and pure SCLC. However, the prognosis for CSCLC was worse than pure SCLC. NGS analysis suggested that CSCLC components might derive from the same pluripotent single clone with common initial molecular alterations and subsequent acquisitions of other genetic mutations.

Keywords: Combined small cell lung cancer (CSCLC); comprehensive genomic profiling; small cell lung cancer (SCLC); targeted gene sequencing.

PubMed Disclaimer

Conflict of interest statement

Conflicts of Interest: All authors have completed the ICMJE uniform disclosure form (available at http://dx.doi.org/10.21037tlcr-20-1099). Dr. JM serves as an unpaid editorial board member of Translational Lung Cancer Research from Aug 2019 to Aug 2021. The authors have no other conflicts of interest to declare.

Figures

Figure 1
Figure 1
The overall survival of pure small cell lung cancer (SCLC) was better than combined small cell lung cancer (CSCLC) (P=0.005).
Figure 2
Figure 2
Representative images of specific markers and the boundary of the different components of combined small cell lung cancer (CSCLC). The left panel shows the staining of small cell lung cancer (SCLC) and adenocarcinoma (AD), while the right panel shows the staining of SCLC and squamous cell carcinoma (SCC).
Figure 3
Figure 3
Summary of gene mutations in combined small cell lung cancer (CSCLC) and pure small cell lung cancer (SCLC). The distribution patterns of single nucleotide variants (top) and copy number variations (bottom) in our study assessed by next-generation sequencing (NGS). Histology and tumor mutation burden (TMB) values of each patient are depicted at the top. H1 in the sample identity (ID) (bottom) represents the component of SCLC; H2 in the sample ID represents the component of non-small cell lung cancer (NSCLC).
Figure 4
Figure 4
The biological process and the pathways of the mutated genes in different components predicted by the Database for Annotation, Visualization and Integrated Discovery (DAVID). (A,B) Images of the biological processes of the mutated genes in the combined small cell lung cancer (CSCLC) and pure small cell lung cancer (SCLC). (C,D) Images of signaling pathways involved in the mutated genes in combined small cell lung cancer (CSCLC) and pure SCLC.
Figure 5
Figure 5
The biological process and the pathways of the mutated genes in different components predicted by the Database for Annotation, Visualization and Integrated Discovery (DAVID). (A,B) Images of the biological processes of the mutated genes in the non-small cell lung cancer (NSCLC) and small cell lung cancer (SCLC) components of combined small cell lung cancer (CSCLC). (C,D) Images of the signaling pathways of the mutated genes in NSCLC and SCLC components of CSCLC.
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Bray F, Ferlay J, Soerjomataram I, et al. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 2018;68:394-424. 10.3322/caac.21492 - DOI - PubMed
    1. Chen W, Zheng R, Baade PD, et al. Cancer statistics in China, 2015. CA Cancer J Clin 2016;66:115-32. 10.3322/caac.21338 - DOI - PubMed
    1. Buys TP, Aviel-Ronen S, Waddell TK, et al. Defining genomic alteration boundaries for a combined small cell and non-small cell lung carcinoma. J Thorac Oncol 2009;4:227-39. 10.1097/JTO.0b013e3181952678 - DOI - PubMed
    1. Jiang C, Shen F, Du J, et al. MicroRNA-564 is downregulated in glioblastoma and inhibited proliferation and invasion of glioblastoma cells by targeting TGF-beta1. Oncotarget 2016;7:56200-8. 10.18632/oncotarget.8987 - DOI - PMC - PubMed
    1. Adelstein DJ, Tomashefski JF, Jr, Snow NJ, et al. Mixed small cell and non-small cell lung cancer. Chest 1986;89:699-704. 10.1378/chest.89.5.699 - DOI - PubMed